據報復星醫藥(02196.HK)不打算再於中國進行新型肺炎疫苗臨床測試
據《路透》報道引述管理層報道,德國BioNTech的中國合作夥伴復星醫藥(02196.HK),不打算將已在中國完成早期試驗的新型肺炎疫苗作進一步臨床測試。
據報復星醫藥首席醫學官回愛民表示,將聚焦於尋求中國批准BioNTech另一款實驗疫苗,該疫苗正於美國進行最後階段的人體試驗。
另外,台灣傳媒報道,台灣東洋日前取得BioNTech的新型肺炎疫苗在台銷售的「有條件授權書」,但由於BioNTech與台灣衛福部對於疫苗的數量與價格仍談不攏,因此宣布無法如期代理疫苗進口。台灣東洋指取得授權後,可就疫苗交貨數量、時間、價格與台灣主管機關協商,但政府採購數量及價格上仍有落差,截至授權協商期滿並未達成共識。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.